Fort Washington Investment Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Fort Washington Investment Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,800	Closed	-$281K	–	525
2020 Q2	$281K	Hold	1,800	–	–	﹤0.01%	444
2020 Q1	$260K	Hold	1,800	–	–	﹤0.01%	381
2019 Q4	$368K	Buy	+1,800	New	+$328K	﹤0.01%	412
2019 Q1	–	Sell	-6,510	Closed	-$365K	–	550
2018 Q4	$365K	Buy	6,510 +1,745	+37%	+$107K	﹤0.01%	423
2018 Q3	$390K	Buy	+4,765	New	+$336K	﹤0.01%	454

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Fort Washington Investment Advisors's RETA Position: Q3 2020 in Review

Fort Washington Investment Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 1,800 shares — an estimated $281K sold.

Fort Washington Investment Advisors first reported a position in RETA in Q3 2018 and held it in 5 quarters. The position peaked at $390K in Q3 2018. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Fort Washington Investment Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Fort Washington Investment Advisors sold 1,800 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $281K.
Fort Washington Investment Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 5 quarters.
Fort Washington Investment Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $390K in Q3 2018.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Fort Washington Investment Advisors's 13F filing for Q3 2020, filed 10 Nov 2020.